NMT Medical gets CE-mark for BioSTAR heart implant
This article was originally published in Clinica
NMT Medical has CE-marked for sale in Europe its BioSTAR device - a bioabsorbable septal repair implant technology and Rapid Transport delivery system. The firm, which has also received Canadian approval for the product, plans to launch BioSTAR in Europe and Canada early in the third quarter of 2007. The BEST (BioSTAR Evaluation Study) clinical trial of the device found that it had closure rates of 92% at 30 days, and 96% at six months, respectively, claimed the Boston, Massachusetts firm.
You may also be interested in...
India has proposed three categories for grouping genetically edited organisms based on the complexity of modifications.
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.